1. Home
  2. OR vs PCVX Comparison

OR vs PCVX Comparison

Compare OR & PCVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

OR

Osisko Gold Royalties Ltd

HOLD

Current Price

$40.10

Market Cap

7.4B

ML Signal

HOLD

Logo Vaxcyte Inc.

PCVX

Vaxcyte Inc.

HOLD

Current Price

$62.79

Market Cap

8.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
OR
PCVX
Founded
2014
2013
Country
Canada
United States
Employees
23
N/A
Industry
Precious Metals
Biotechnology: Pharmaceutical Preparations
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.4B
8.7B
IPO Year
2014
2020

Fundamental Metrics

Financial Performance
Metric
OR
PCVX
Price
$40.10
$62.79
Analyst Decision
Hold
Strong Buy
Analyst Count
4
5
Target Price
$47.00
$88.25
AVG Volume (30 Days)
1.0M
1.2M
Earning Date
05-06-2026
05-06-2026
Dividend Yield
0.56%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$100.08
N/A
Revenue Next Year
$13.87
N/A
P/E Ratio
$55.77
N/A
Revenue Growth
N/A
N/A
52 Week Low
$22.08
$28.09
52 Week High
$48.06
$65.00

Technical Indicators

Market Signals
Indicator
OR
PCVX
Relative Strength Index (RSI) 53.74 65.54
Support Level $38.38 $42.30
Resistance Level $42.25 $65.00
Average True Range (ATR) 1.62 2.28
MACD 0.50 0.62
Stochastic Oscillator 72.41 95.44

Price Performance

Historical Comparison
OR
PCVX

About OR Osisko Gold Royalties Ltd

OR Royalties Inc is engaged in the business of acquiring and managing precious metal and other high-quality royalties, streams and similar interests. The Company owns a portfolio of royalties, streams, offtakes, options on royalty/stream financings and exclusive rights to participate in future royalty/stream financings on various projects. Geographically, it generates majority of its income from North America and also generates some portions of income from South America, Australia, Africa and Europe.

About PCVX Vaxcyte Inc.

Vaxcyte Inc is a clinical-stage vaccine company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It uses the XpressCF cell-free protein synthesis platform to develop potentially superior and novel conjugate and protein vaccine candidates for adult and pediatric indications. The company's product pipeline includes: VAX-31, VAX-24, and VAX-XL PCV vaccine candidates; VAX-A1, a Novel Group A Strep Vaccine; and VAX-GI, a Novel Shigella Vaccine, among others, in their different stages of development.

Share on Social Networks: